Developing a drug or biologic can become more expensive and time-consuming than expected. Often, companies struggle with the regulatory pathways for a drug or biologic because of the ambiguity and complexity of the process, coupled with the preclinical, GMP manufacturing, and clinical testing requirements. Additionally, many companies fail to understand the needs of investors and strategic partners.

This session will cover: